Sustained Elevation of Kynurenic Acid in the Cerebrospinal Fluid of Patients with Herpes Simplex Virus Type 1 Encephalitis

International Journal of Tryptophan Research

Volumn 6, Issue , 2013, Pages

  Atlas, Ann ^a   Franzen Röhl, Elisabeth ^a   Söderlund, Johan ^b   Jönsson, Erik G ^b   Samuelsson, Martin ^c   Schwieler, Lilly ^b   Sköldenberg, Birgit ^a   Engberg, Göran ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

cognition; HSE; neurodegeneration; NMDA hypofunction; Tryptophan

Indexed keywords

EID: 84919402466     PISSN: None     EISSN: 11786469     Source Type: Journal    
DOI: 10.4137/IJTR.S13256     Document Type: Article

References (69)

1. Sköldenberg B. Herpes simplex encephalitis. Scand J Infect Dis Suppl. 1991; 80: 40–6.
2. Whitley R.J., Roizman B. Herpes simplex virus infections. Lancet. 2001; 357(9267): 1513–8.
3. Tyler K.L. Herpes simplex virus infections of the central nervous system: encephalitis and meningitis, including Mollaret's. Herpes. 2004; 11 Suppl 2: 57A–64A.
4. Sköldenberg B. Herpes simplex encephalitis. Scand J Infect Dis Suppl. 1996; 100: 8–13.
5. Whitley R.J., Kimberlin D.W. Herpes simplex encephalitis: children and adolescents. Semin Pediatr Infect Dis. 2005; 16(1): 17–23.
6. Whitley R.J. Herpes simplex encephalitis: adolescents and adults. Antiviral Res. 2006; 71(2-3): 141–8.
7. Whitley R.J., Soong S.J., Lineman C. Jr, Liu C., Pazin G., Alford C.A. Herpes Simplex Encephalitis. Clin Assment. JAMA. 1982; 247: 317–20.
8. Kohl S. Herpes simplex virus encephalitis in children. Pediatr Clin North Am. 1988; 35(3): 465–83.
9. Sköldenberg B., Forsgren M., Alestig K. et al. Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients. Lancet. 1984; 2(8405): 707–11.
10. Whitley R.J., Alford C.A., Hirsch M.S. et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med. 1986; 314(3): 144–9.
11. Raschilas F., Wolff M., Delatour F. et al. Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study. Clin Infect Dis. 2002; 35(3): 254–60.
12. Damasio A.R., Van Hoesen G.W. The limbic system and the localisation of herpes simplex encephalitis. J Neurol Neurosurg Psychiatry. 1985; 48(4): 297–301.
13. Gordon B., Selnes O.A., Hart J., Hanley D.F., Whitley R.J. Long-term cognitive sequelae of acyclovir-treated herpes simplex encephalitis. Arch Neurol. 1990; 47(6): 646–7.
14. McGrath N., Anderson N.E., Croxson M.C., Powell K.F. Herpes simplex encephalitis treated with acyclivir. diagnosis and long term outcome. J Neurol Neurosurg Psychiat 1997; 63: 321–6.
15. Domingues R.B., Tsanaclis A.M., Pannuti C.S., Mayo M.S., Lakeman F.D. Evaluation of the range of clinical presentations of herpes simplex encephalitis by using polymerase chain reaction assay of cerebrospinal fluid samples. Clin Infect Dis. 1997; 25(1): 86–91.
16. Hjalmarsson A., Blomqvist P., Sköldenberg B. Herpes simplex encephalitis in Sweden, 1990–2001: incidence, morbidity, and mortality. Clin Infect Dis. 2007; 45(7): 875–80.
17. Koelle D.M., Corey L. Recent Progress in Herpes Simplex Virus. Clinical Microbiology Review. 2003; 1: 96–113.
18. Pass R.F., Whitely R.J., Whelchel J.D., Diethelm A.G., Reinholds D.W., Alford C.A. Identification of patients with ioncreased risk of infecltion with herpes simplex virus after renal transplantation. J Infect Dis. 1979; 140: 487–92.
19. Conley M.E., Broides A., Hernande–Trujillo V. et al. Genetic analysis of patients with defects oin early B-cell development. Immunol Rev. 2005; 203: 216–34.
20. Casrouge A., Zhamg S.Y., Eidenschenk C. et al. Herpes simplex virus encephalitis in humans UNC-93B deficiency. Science. 2006; 314: 308–12.
21. Leklem J.E. Quantitative aspects of tryptophan metabolism in humans and other species: a review. Am J Clin Nutr. 1971; 24(6): 659–72.
22. Raison C.L., Dantzer R., Kelley K.W. et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-a: relationship to CNS immune responses and depression. Mol Psychiatry. 2010; 15: 399–403.
23. Schwarcz R., Bruno J.P., Muchowski P.J., Wu H.Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012; 13(7): 465–77.
24. Schröcksnadel K., Wirleitner B., Winkler C., Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta. 2006; 364(1-2): 82–90.
25. Birch P.J., Grossman C.J., Hayes A.G. Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol. 1988; 154(1): 85–7.
26. Kessler M., Terramani T., Lynch G., Baudry M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem. 1989; 52(4): 1319–28.
27. Parsons C.G., Danysz W., Quack G. et al. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther. 1997; 283(3): 1264–75.
28. Hilmas C., Pereira E.F., Alkondon M., Rassoulpour A., Schwarcz R., Albuquerque E.X. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci. 2001; 21(19): 7463–73.
29. Foster N.L., Chase T.N., Mansi L. et al. Cortical abnormalities in Alzheimer's disease. Ann Neurol. 1984; 16: 649–54.
30. Erhardt S., Schwieler L., Emanuelsson C., Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry. 2004; 56(4): 255–60.
31. Chess A.C., Simoni M.K., Alling T.E., Bucci D.J. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull. 2007; 33(3): 797–804.
32. Akagbosu C.O., Evans G.C., Gulick D., Suckow R.F., Bucci D.J. Exposure to kynurenic acid during adolescence produces memory deficits in adulthood. Schizophr Bull. 2012; 38(4): 769–78.
33. Alexander K.S., Wu H.Q., Schwarcz R., Bruno J.P. Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology (Berl). 2012; 220(3): 627–37.
34. Erhardt S., Olsson S.K., Engberg G. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs. 2009; 23(2): 91–101.
35. Holze M., Mickienie A., Atlas A., Lindqvist L., Schwieler L. Elevated cerebrospinal fluid kynurenic acid levels in patients with tick borne encephalitis. J Intern Med. 2012; 272: 394–401.
36. Atlas A., Gisslén M., Nordin C., Lindström L., Schwieler L. Acute psychotic symptoms in HIV-1 infected patients are associated with increased levels of kynurenic acid in cerebrospinal fluid. Brain Behav Immun. 2007; 21(1): 86–91.
37. Erhardt S., Blennow K., Nordin C., Skogh E., Lindström L.H., Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett. 2001; 313(1-2): 96–8.
38. Schwarcz R., Rassoulpour A., Wu H.Q., Medoff D., Tamminga C.A., Roberts R.C. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry. 2001; 50(7): 521–30.
39. Nilsson L.K., Linderholm K.R., Engberg G. et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male pateints with schizophrenia. Schizophr Res. 2005; 15: 2315–22.
40. Linderholm K.R., Skogh E., Olsson S.K. et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull. 2012; 38(3): 426–32.
41. Olsson S.K., Samuelsson M., Saetre P. et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J Psychiatry Neurosci. 2010; 35(3): 195–9.
42. Maccallum F.O., Potter J.M., Edwards D.H. Early diagnosis of herpes-simplex encephalitis by brain biopsy. Lancet. 1964; 2(7355): 332–4.
43. Cinque P., Cleator G.M., Weber T., Monteyne P., Sindic C.J., van Loon A.M. The role of laboratory investigation in the diagnosis and management of patients with suspected herpes simplex encephalitis: a consensus report. The EU Concerted Action on Virus Meningitis and Encephalitis. J Neurol Neurosurg Psychiatry. 1996; 61(4): 339–45.
44. Heyes M.P., Quearry B.J. Quantification of kynurenic acid in cerebrospinal fluid: effects of systemic and central L-kynurenine administration. J Chromatogr. 1990; 530(1): 108–15.
45. Guillemin G.J., Smythe G., Takikawa O., Brew B.J. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia. 2005; 49(1): 15–23.
46. Aurelius E., Andersson B., Forsgren M., Sköldenberg B., Strannegård O. Cytokines and other markers of intrathecal immune response in patients with herpes simplex encephalitis. J Infect Dis. 1994; 170(3): 678–81.
47. Ichiyama T., Shoji H., Takahashi Y. et al. Cerebrospinal fluid levels of cytokines in non-herpetic acute limbic encephalitis: comparison with herpes simplex encephalitis. Cytokine. 2008; 44(1): 149–53.
48. Reinhard J.F. Altered tryptophan metabolism in mice with herpes simplex virus encephalitis: increases in spinal cord quinolinic acid. Neurochem Res. 1998; 23(5): 661–5.
49. Stone T.W., Forrest C.M., Darlington L.G. Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS J. 2012; 279(8): 1386–97.
50. Pfefferkorn E.R. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cell to degradate tryptophan. Proc Natl Acad Sci USA. 1984; 81: 908–12.
51. Matteoli G., Mazzini E., Iliev I.D. et al. Gut CD103+ dendritic cells express indoleamine 2, 3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut. 2010; 59: 595–604.
52. Yan Y., Zhang G.X., Gran B. et al. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J Immunol. 2010; 185(10): 5953–61.
53. Wilczynski J.R., Radwan M., Kalinka J. The characterization and role of regulatory T cells in immune reactions. Front Biosci. 2008; 13: 2266–74.
54. Potula R., Poluektova L., Knipe B. et al. Inhibition of indoleamine 2, 3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood. 2005; 106: 2382–90.
55. Stone T.W., Perkins M.N. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol. 1981; 72(4): 411–2.
56. Schwarcz R., Köhler C. Differential vulnerability of central neurons of the rat to quinolinic acid. Neurosci Lett. 1983; 38(1): 85–90.
57. Reinhard J.F., Flanagan E.M. The neurotoxin quinolinic acid is increased in spinal cords of mice with herpes simplex virus encephalitis. Adv Exp Med Biol. 1996; 398: 241–6.
58. Sapko M.T., Guidetti P., Ju P., Tagle D.A., Pelliccjari R., Schwarcz R. Endogenous qunurenate controls the vulnerability of striatal neurons to quinolinate: implications for Huntington's disease. Exp Neurol. 2006; 197: 31–40.
59. Erhardt S., Schwieler L., Nilsson L., Linderholm K., Engberg G. The kynurenic acid hypothesis of schizophrenia. Physiol Behav. 2007; 92(1-2): 203–9.
60. Olsson S.K., Sellgren C., Engberg G., Landén M., Erhardt S. Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord. 2012; 14(7): 719–26.
61. Robbins T.W., Murphy E.R. Behavioural pharmacology: 40+ years of progress, with a focus on glutamate receptors and cognition. Trends Pharmacol Sci. 2006; 27(3): 141–8.
62. Robinson R.G., Smith S.M., Wolkensberg S.E. et al. Characterization of Non-nitrocatechol pan and isoform specific catechol-o-methyltransferase inhibitors and substrates. ACS Chem Neurosci. 2011; 3: 129–40.
63. Potter M.C., Elmer G.I., Bergeron R. et al. Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology. 2010; 35(8): 1734–42.
64. Nakamura T., Niimi S., Nawa K. et al. Multihormonal regulation of transcription of the tryptophan 2,3-dioxygenase gene in primary cultures of adult rat hepatocytes with special reference to the presence of a transcriptional protein mediating the action of glucocorticoids. J Biol Chem. 1987; 262(2): 727–33.
65. Türck J., Oberdörfer C., Vogel T., Mackenzie C.R., Däubener W. Enhancement of antimicrobial effects by glucocorticoids. Med Microbiol Immunol. 2005; 194(1-2): 47–53.
66. Liao M., Pabarcus M.K., Wang Y. et al. Impaired dexamethasone-mediated induction of tryptophan 2,3-dioxygenase in heme-deficient rat hepatocytes: translational control by a hepatic eIF2alpha kinase, the heme-regulated inhibitor. J Pharmacol Exp Ther. 2007; 323(3): 979–89.
67. Kocki T., Wielosz M., Turski W.A., Urbanska E.M. Enhancement of brain kynurenic acid production by anticonvulsants–novel mechanism of antiepileptic activity? Eur J Pharmacol. 2006; 541(3): 147–51.
68. Müller A.C., Dairam A., Limson J.L., Daya S. Mechanisms by which acyclovir reduces the oxidative neurotoxicity and biosynthesis of quinolinic acid. Life Sci. 2007; 80(10): 918–25.
69. Müller C., Daya S. Acyclovir inhibits rat liver tryptophan-2,3-dioxygenase and induces a concomitant rise in brain serotonin and 5-hydroxyindole acetic acid levels. Metab Brain Dis. 2008; 23: 351–60.